Key Highlights

  • The fund holds 67 global companies working on neurological disorders.
  • Biogen, Edgewise Therapeutics and Neurocrine Biosciences are among the largest positions.
  • Net asset value is $34.92, after a one-day gain of $1.06, or 3.12%.
  • The expense ratio is 0.47%, and distributions are paid annually.

Neurological disorders remain a major area of medical research, and the iShares Neuroscience and Healthcare ETF (NYSEARCA:IBRN) offers exposure to companies advancing research and treatment in brain health. Figures in this article are current to November 9, 2026. The fund seeks to track an index that includes global companies focused on neuroscience biopharmaceuticals and medical technology. Shares trade on NYSE Arca and have been listed since August 2022.

Fund Fact

Detail

Exchange and ticker

NYSE Arca: IBRN

Fund inception

August 24, 2022

Net assets

$8.7 million

Net asset value

$34.92

Daily NAV change

+$1.06 (+3.12%)

Expense ratio

0.47%

12-month trailing yield

0.96%

Distribution frequency

Annual

Number of holdings

67

Leading Biopharma Positions

Biogen accounts for about 5.4% of market value, Edgewise Therapeutics 5.2% and Neurocrine Biosciences 5.0%. Alkermes, Praxis Precision Medicines and PTC Therapeutics also rank among the largest holdings.

Argenx, Scholar Rock Holding, Axogen and Dianthus Therapeutics round out the top ten. Most of the leading positions are drug developers, which gives the fund a clinical-stage profile.

Trading and Price Movement

The net asset value rose $1.06 in the latest session, a gain of 3.12%. Average Daily Volume is about 3,600 shares, and the 30-day median bid-ask spread of 0.31% is wider than in many healthcare funds.

The premium or discount to NAV was -0.16 in recent figures, so shares traded slightly below the value of holdings. Investors may find that spreads matter more on smaller orders.

Costs, Distributions and Clinical Risk

The expense ratio is 0.47%, consisting of a management fee of the same amount. Distributions are paid annually, and the 12-month trailing Yield of 0.96% reflects a limited income profile.

Healthcare companies face regulatory approvals, clinical trial results and competitive pressures. Drug developers in particular can see large price moves on trial data, and the fund's Standard Deviation of 24.2% reflects that exposure.

Final Word

The iShares Neuroscience and Healthcare ETF offers a focused, global view of companies working on brain health, with many of its holdings in clinical-stage drug developers. Its annual distribution, moderate fee and wider trading spread define its profile. Investors will weigh this specialized healthcare theme against their broader sector exposure.